|
|
|
|
Staphylococcal enterotoxin-like X (SElX) is a unique superantigen with functional features of two major families of staphylococcal virulence factors
|
|
|
|
|
|
|
|
نویسنده
|
langley r.j. ,ting y.t. ,clow f. ,young p.g. ,radcliff f.j. ,choi j.m. ,sequeira r.p. ,holtfreter s. ,baker h. ,fraser j.d.
|
|
منبع
|
plos pathogens - 2017 - دوره : 13 - شماره : 9
|
|
چکیده
|
Staphylococcus aureus is an opportunistic pathogen that produces many virulence factors. two major families of which are the staphylococcal superantigens (sags) and the staphylococcal superantigen-like (ssl) exoproteins. the former are immunomodulatory toxins that induce a vβ-specific activation of t cells,while the latter are immune evasion molecules that interfere with a wide range of innate immune defences. the superantigenic properties of staphylococcal enterotoxin-like x (selx) have recently been established. we now reveal that selx also possesses functional characteristics of the ssls. a region of selx displays high homology to the sialyl-lactosamine (slacnac)-specific binding site present in a sub-family of ssls. by analysing the interaction of selx with slacnac-containing glycans we show that selx has an equivalent specificity and host cell binding range to the ssls. mutation of key amino acids in this conserved region affects the ability of selx to bind to cells of myeloid origin and significantly reduces its ability to protect s. aureus from destruction in a whole blood killing (wbk) assay. like the ssls,selx is up-regulated early during infection and is under the control of the s. aureus exotoxin expression (sae) two component gene regulatory system. additionally,the structure of selx in complex with the slacnac-containing tetrasaccharide sialyl lewis x (slex) reveals that selx is a unique single-domain sag. in summary,selx is an ‘ssl-like’ sag. © 2017 langley et al.
|
|
|
|
|
آدرس
|
school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand, school of biological sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland,new zealand,department of biochemistry and molecular biology,monash university,melbourne, Australia, school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand, school of biological sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand, school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand, school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand, school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland,new zealand,department of medicine,imperial college,london, United Kingdom, school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland,new zealand,department of immunology,university medicine greifswald,greifswald, Germany, school of biological sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand, school of medical sciences and the maurice wilkins centre for molecular biodiscovery,the university of auckland,auckland, New Zealand
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|